EUVIMEDEUVIMED entdecken
Crossref

Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Beatriz Cirauqui Cirauqui iD, Adrià Bernat Peguera, Ariadna Quer Pi-Sunyer, Angelica Ferrando-Díez, Jose Luis Ramírez Serrano, Marta Domenech Viñolas, Iris Teruel García, Vanesa Quiroga García, Imane Chaib Oukadour, Andrea González Valencia, Pilar Hernández Vergara, Itziar de Aguirre Egaña und 8 weitere

Head & Neck · 2025

DOI: 10.1002/hed.27892 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Beatriz Cirauqui Cirauqui und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Catalan Institute of Oncology (ICO), Badalona, Spain. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Paclitaxel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Squamous cell carcinoma of the head and neck (SCCHN) is an aggressive disease with poor prognosis. It is known that the activation of STAT3 signaling pathways promotes the development and progression of this neoplasia and it has been described the role of PTPRT as a negative regulator of STAT3. Then, we have evaluated the impact of them as biomarkers of outcome in a series of patients with recurrent and/or metastatic SCCHN treated with weekly paclitaxel‐plus‐cetuximab (ERBITAX) regimen. Patients and methods Between 2008 and 2017, 52 patients with recurrent/metastatic SCCHN were treated with ERBITAX at our center, 34 of whom had available tumor samples. Phosphorylated STAT3 (pSTAT3) protein expression was analyzed by immunohistochemistry, STAT3 mRNA expression by qPCR, and PTPRT promoter methylation by methylation‐specific PCR. Molecular results were correlated with response rate (RR), progression‐free survival (PFS), and overall survival (OS). Results pSTAT3 overexpression was detected in 67% and PTPRT promoter hypermethylation in 41% of tumor samples. PTPRT promoter hypermethylation showed a trend towards an association with lower RR (21% vs. 60%; p = 0.06). A lower RR was also observed in patients with pSTAT3 overexpression (36% vs. 54%) and in those with high STAT3 mRNA levels (43% vs. 64%), but these differences did not reach statistical significance. PTPRT promoter hypermethylation correlated with pSTAT3 overexpression ( p = 0.009) but not with STAT3 mRNA overexpression. OS and PFS was shorter in patients with activated STAT3, but the difference did not reach statistical significance.

Conclusions

Although this was a relatively small retrospective study, it provides preliminary indications of the potential role of the STAT3 pathway on outcome in SCCHN and confirms that PTPRT acts as a negative regulator of STAT3. Our findings warrant investigation in a larger patient cohort to determine if inactivating this pathway through specific targeted treatments could improve outcomes in recurrent/metastatic SCCHN patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsPaclitaxelNeoplasm Recurrence, LocalDNA MethylationCetuximabBiomarkers, TumorHumansFemaleMaleMiddle AgedAgedAdultAntineoplastic Combined Chemotherapy ProtocolsRetrospective StudiesPromoter Regions, Genetic

Stichwörter der Autor:innen

PTPRTSTAT3cetuximabmethylationpaclitaxelsquamous cell carcinoma of the head and neck

Substanzen

STAT3 Transcription FactorPaclitaxelCetuximabSTAT3 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology, Catalan Institute of Oncology (ICO), Badalona, Spain.
  • Badalona Applied Research Group in Oncology (BARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • Translational Program in Cancer Research (CARE), Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • Head and Neck Functional Unit, Catalan Institute of Oncology (ICO), Badalona, Spain.
  • Department of Pathology, Germans Trias i Pujol Hospital, Badalona, Spain.
  • Molecular Biology Unit, Hematology Laboratory, Catalan Institute of Oncology (ICO), Badalona, Spain.

ORCID-Profile: Beatriz Cirauqui Cirauqui

Zitieren

APA

Cirauqui, B. C., Peguera, A. B., Pi-Sunyer, A. Q., Ferrando-Díez, A., Serrano, J. L. R., Viñolas, M. D., García, I. T., García, V. Q., Oukadour, I. C., Valencia, A. G., Vergara, P. H., de Aguirre Egaña, I., Herrero, C. Q., Carbonell, O. M., Paradís, A. L., Esteve, A., Vila, M. M., Rosell, R., Martínez-Cardús, A., & Mesía, R. (2025). Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head & Neck. https://doi.org/10.1002/hed.27892

Vancouver

Cirauqui BC, Peguera AB, Pi-Sunyer AQ, Ferrando-Díez A, Serrano JLR, Viñolas MD, et al. Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head & Neck. 2025. doi:10.1002/hed.27892

BibTeX
@article{Cirauqui2025,
  author = {Cirauqui, Beatriz Cirauqui and Peguera, Adrià Bernat and Pi-Sunyer, Ariadna Quer and Ferrando-Díez, Angelica and Serrano, Jose Luis Ramírez and Viñolas, Marta Domenech and García, Iris Teruel and García, Vanesa Quiroga and Oukadour, Imane Chaib and Valencia, Andrea González and Vergara, Pilar Hernández and de Aguirre Egaña, Itziar and Herrero, Cristina Queralt and Carbonell, Oscar Mesía and Paradís, Assumpció López and Esteve, Anna and Vila, Mireia Margelí and Rosell, Rafael and Martínez-Cardús, Anna and Mesía, Ricard},
  title = {Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.27892}
}
Kostenlos starten →